Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy.

MLA

Brener, Avivit, et al. “Cardiovascular Health in Pediatric Patients with X-Linked Hypophosphatemia under Two Years of Burosumab Therapy.” Frontiers in Endocrinology, vol. 15, May 2024, p. 1400273. EBSCOhost, https://doi.org/10.3389/fendo.2024.1400273.

APA

Brener, A., Cleper, R., Baruch, G., Rothschild, E., Yackobovitch-Gavan, M., Beer, G., Zeitlin, L., & Kapusta, L. (2024). Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy. Frontiers in Endocrinology, 15, 1400273. https://doi.org/10.3389/fendo.2024.1400273

Chicago

Brener, Avivit, Roxana Cleper, Guy Baruch, Ehud Rothschild, Michal Yackobovitch-Gavan, Gil Beer, Leonid Zeitlin, and Livia Kapusta. 2024. “Cardiovascular Health in Pediatric Patients with X-Linked Hypophosphatemia under Two Years of Burosumab Therapy.” Frontiers in Endocrinology 15 (May): 1400273. doi:10.3389/fendo.2024.1400273.